TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, is pleased to announce the Company will release its Fiscal Fourth Quarter and Year End 2023 financial results for the period ended December 31, 2023, on Thursday, March 28, 2024. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at 1:00 pm EST (10:00 am PST). The call will be hosted by Dr. Alexander Dobranowski, Chief Executive Officer, and Scott Nirenberski, Chief Financial Officer. Please dial in 10 minutes prior to the start of the call.
Date: Thursday, March 28, 2024
Time: 1:00 PM ET / 10:00 AM PT
For attendees who wish to join by webcast, the event can be accessed at: https://edge.media-server.com/mmc/p/kh2csfpp
Attendees who wish to join by phone must visit the following link and pre-register: https://register.vevent.com/register/BI6c778943adc34c2382f3833fb2d87a3b
Instructions for joining by phone:
Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI
About HEALWELL
HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange (the “TSX”) under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit https://healwell.ai/.
For more information:
Pardeep Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 416-440-4040 x.201
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$1.77 |
Daily Change: | -0.05 -2.75 |
Daily Volume: | 379,082 |
Market Cap: | C$293.610M |
December 03, 2024 November 12, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load